Go Pro

Tvardi Therapeutics (TVRD) Earnings Date, Estimates & Call Transcripts

Tvardi Therapeutics logo
$1.81 -0.05 (-2.69%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tvardi Therapeutics Earnings Summary

Tvardi Therapeutics issued Q2 2026 earnings on August 14, 2026, reporting an EPS of -$0.69, which missed analysts' consensus estimates of -$0.65 by $0.04. With a trailing EPS of -$2.79, Tvardi Therapeutics' earnings are expected to decrease next year, from ($2.35) to ($2.78) per share.

Q2 2026 Earnings Resources

Consensus EPS
(Aug. 14)
-$0.65
Actual EPS
(Aug. 14)
-$0.69 Missed By -$0.04
Get Tvardi Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tvardi Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

TVRD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Tvardi Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20261-$0.78-$0.78-$0.78
Q3 20261-$0.61-$0.61-$0.61
Q4 20261-$0.54-$0.54-$0.54

Tvardi Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026-$0.65-$0.69 -$0.04-$0.69--
5/8/2026Q1 2026-$0.65-$0.73 -$0.08-$0.73--
3/31/2026Q4 2025-$0.55-$0.78 -$0.23-$0.78--
11/13/2025Q3 2025-$0.83-$0.59+$0.24-$0.59--
8/14/2025Q2 2025-$0.51-$1.00 -$0.49-$1.00--

Tvardi Therapeutics Earnings - Frequently Asked Questions

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earning data on Friday, August 14, 2026. Learn more on TVRD's earnings history.

In the previous quarter, Tvardi Therapeutics (NASDAQ:TVRD) missed the analysts' consensus estimate of ($0.65) by $0.04 with a reported earnings per share (EPS) of ($0.69). Learn more on analysts' earnings estimate vs. TVRD's actual earnings.

Tvardi Therapeutics (NASDAQ:TVRD) has a recorded net income of -$18.21 million. TVRD has generated -$2.79 earnings per share over the last four quarters.

Tvardi Therapeutics' earnings are expected to decrease from ($2.35) per share to ($2.78) per share in the next year.


Earnings data for NASDAQ:TVRD is sourced from Fiscal.ai, with the most recent quarter reported on 8/14/2026. New results are added as companies report their earnings.
From Our Partners